David Rose

Mr. David Rose


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2010 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
FBFederico Bizzarri
Federico Bizzarri
ATAntonella Tudisco
Antonella Tudisco
MRMassimo Ricci
Massimo Ricci
DRDavid Rose
David Rose
Giacomo FratiGiacomo Frati
Giacomo Frati
Myxomatous mitral regurgitation (type II Carpentier's functional classification) affects about 1-2% of the population. This represents a very common indication for valve surgery resulting in a low percentage of repairs compared to replacement which is actually performed. In the last decades, several methods for mitral valve repair have been developed, to make the surgical feasibility easier, improve the long-term follow-up thus avoiding the need for reoperations. A very interesting method is represented by the combination of various valve repair techniques, depending on the involvement of the anterior, posterior, or both leaflets, and the use of PTFE artificial chordae tendineae when excessive chordal elongation or rupture due to myxomatous degeneration co-exists. The aim of this review is to summarize the evolution of these techniques from the beginning till now.

1 May 2021 in JACC
Verified
Journal Article
Closed access
MVMattia Vinciguerra
Mattia Vinciguerra
CSCristiano Spadaccio
Cristiano Spadaccio
CTCharlene Tennyson
Charlene Tennyson
MKMukesh Karuppannan
Mukesh Karuppannan
ABAmal Bose
Amal Bose
DRDavid Rose
David Rose

Verified
Journal Article
Open access
PDF file
MVMattia Vinciguerra
Mattia Vinciguerra
SRSilvia Romiti
Silvia Romiti
Sangiorgi Giuseppe MassimoSangiorgi Giuseppe Massimo
Sangiorgi Giuseppe Massimo
DRDavid Rose
David Rose
FMFabio Miraldi
Fabio Miraldi
Ernesto GrecoErnesto Greco
Ernesto Greco
At the beginning of the COVID-19 pandemic, the lung was recognized as the main target organ; now, new evidence suggests that SARS-CoV-2 infection leads to vascular disease. In a previous review, we supposed a bidirectional link between endothelial dysfunction and COVID-19, identifying atherosclerosis as having a crucial role in its pathogenesis. Atherosclerosis with an existing endothelial dysfunction may worsen COVID-19 manifestations, leading to adverse outcomes, as largely reported. However, COVID-19 may be the trigger factor in the progression of the atherosclerotic process up to making it clinically manifest. The thrombotic complications can involve not only the atherosclerotic plaque, but also the durability of the surgical device implanted to treat a pre-existing coronary artery disease as recently reported. The burden of the disease makes necessary a long-term stratification of patients, revising drastically targeted therapy among others.

8 October 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Antonino GM MarulloAntonino GM Marullo
Antonino GM Marullo
FIFrancesco Giosuè Irace
Francesco Giosuè Irace
PVPiergiusto Vitulli
Piergiusto Vitulli
MPMariangela Peruzzi
Mariangela Peruzzi
DRDavid Rose
David Rose
EGErnesto Greco
Ernesto Greco
Intraluminal aortic clamping has been achieved until now by means of a sophisticated device consisting of a three-lumen catheter named Endoclamp, which allows at the same time occlusion of the aorta, antegrade delivering of cardioplegia, and venting through the aortic root. This tool has shown important advantages allowing aortic occlusion and perfusate delivering without a direct contact with ascending aorta reducing meanwhile the risk of traumatic and/or iatrogenic injuries. Recently, a new device (Intraclude catheter) with the same characteristics and properties has been proposed and introduced in clinical practice. The aim of this paper is to investigate the differences between Endoclamp and Intraclude catheters and to analyze the advantages advocated by this new device for intraluminal aortic occlusion since it is noticeable as these new technological tools are gaining more and more attractiveness due to their appraised clinical efficacy.

20 March 2016 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
DRDavid Rose
David Rose
APAnselmo Papa
Anselmo Papa
STSilverio Tomao
Silverio Tomao
EGErnesto Greco
Ernesto Greco
JZJoseph Zacharias
Joseph Zacharias
We describe two cases of cardiac myxomas with cerebral metastases and review the literature on this subject. doi: 10.1111/jocs.12727 (J Card Surg 2016;31:289-293).

Verified
Journal Article
Open access
PDF file
Antonio NennaAntonio Nenna
Antonio Nenna
ALAlice Laudisio
Alice Laudisio
CTChiara Taffon
Chiara Taffon
MFMarta Fogolari
Marta Fogolari
Cristiano SpadaccioCristiano Spadaccio
Cristiano Spadaccio
MLMario Lusini
Mario Lusini
The high incidence of atrial fibrillation (AFib) following cardiac surgery (postoperative atrial fibrillation, POAF) relies on specific surgical features. However, in the setting of POAF, the role of the microbiome in the modulation of cardiac fibrosis is still not clear. This study aimed to analyze the effect of the microbiome and its main metabolic product (trimethylamine-N-oxide, TMAO) in the fibrosis of myocardial tissue, to investigate its role in POAF. Patients undergoing elective cardiac surgery with cardiopulmonary bypass, central atrio-caval cannulation and no history of AFib, were included. A fragment of the right atrium was analyzed for qualitative and mRNA-quantitative evaluation. A preoperative blood sample was analyzed with enzyme-linked immunosorbent assay (ELISA). A total of 100 patients have been included, with POAF occurring in 38%. Histologically, a higher degree of fibrosis, angiogenesis and inflammation has been observed in POAF. Quantitative evaluation showed increased mRNA expression of collagen-1, collagen-3, fibronectin, and transforming growth factor beta (TGFb) in the POAF group. ELISA analysis showed higher levels of TMAO, lipopolysaccharide and TGFb in POAF, with similar levels of sP-selectin and zonulin. TMAO ≥ 61.8 ng/mL (odds ratio, OR 2.88 [1.35–6.16], p = 0.006), preoperative hemoglobin < 13.1 g/dL (OR 2.37 [1.07–5.24], p = 0.033) and impaired right ventricular function (OR 2.38 [1.17–4.83], p = 0.017) were independent predictors of POAF. Also, TMAO was significantly associated with POAF by means of increased fibrosis. Gut microbiome product TMAO is crucial for myocardial fibrosis, which is a key factor for POAF. Patients in preoperative sinus rhythm who will develop POAF have increased genetic expression of pro-fibrotic genes and enhanced fibrosis in histological staining. Elevated TMAO level (≥61.8 ng/mL) is an independent risk factor for POAF.